Payment overview · 2025
General Payments
$2,203.13
80 reported records · 20 companies
Healthcare provider profile · identity verified
Kenneth I Levy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHOENIX, AZ · NPI 1174712806
Verified facts
What the public records show
CMS Open Payments records show Kenneth I Levy, MD received $2,203.13 in general payments during 2025 across 80 reported records.
Novo Nordisk Inc accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $388.35 | 17.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $287.24 | 13.0% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $228.78 | 10.4% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $224.55 | 10.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $192.84 | 8.8% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $163.04 | 7.4% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $162.78 | 7.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.39 | 4.3% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $78.49 | 3.6% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.89 | 3.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.07 | 2.8% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $48.56 | 2.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.00 | 2.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.99 | 1.5% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $25.92 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.29 | 0.9% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $19.15 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.00 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.15 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.65 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,203.13 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $228.78 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $224.55 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $220.34 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $175.76 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $168.01 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $163.04 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $162.78 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $127.39 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.12 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $95.34 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $79.98 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $78.49 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.52 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.52 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $64.11 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.07 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.07 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $48.56 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.99 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $13.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 59 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
112 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 38 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 584 | 184 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 520 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 469 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 136 |
| Celecoxib | Celecoxib | 365 | 92 |
| Gabapentin | Gabapentin | 359 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 349 | 125 |
| Metformin Hcl | Metformin Hcl | 207 | 63 |
| Tramadol Hcl | Tramadol Hcl | 198 | 51 |
| Lisinopril | Lisinopril | 188 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 161 | 51 |
| Sertraline Hcl | Sertraline Hcl | 157 | 47 |
| Trazodone Hcl | Trazodone Hcl | 142 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 18 |
| Eliquis | Apixaban | 134 | 38 |
| Furosemide | Furosemide | 130 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 42 |
| Ozempic | Semaglutide | 126 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 40 |
| Mounjaro | Tirzepatide | 112 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 37 |
| Spironolactone | Spironolactone | 106 | 39 |
| Carvedilol | Carvedilol | 105 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 25 |
| Azithromycin | Azithromycin | 102 | 74 |
| Omeprazole | Omeprazole | 95 | 31 |
| Donepezil Hcl | Donepezil Hcl | 94 | 27 |
| Azelastine Hcl | Azelastine Hcl | 90 | 50 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 58 |
| Alprazolam | Alprazolam | 88 | 24 |
| Simvastatin | Simvastatin | 88 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 28 |
| Famotidine | Famotidine | 86 | 38 |
| Montelukast Sodium | Montelukast Sodium | 83 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 48 |
| Ezetimibe | Ezetimibe | 76 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 23 |
| Mirtazapine | Mirtazapine | 71 | 29 |
| Nifedipine Er | Nifedipine | 71 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 19 |
| Linzess | Linaclotide | 59 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 57 | 15 |
| Ketoconazole | Ketoconazole | 57 | 30 |
| Myrbetriq | Mirabegron | 57 | 15 |
| Pregabalin | Pregabalin | 57 | 15 |
| Ibuprofen | Ibuprofen | 56 | 15 |
| Labetalol Hcl | Labetalol Hcl | 56 | 15 |
| Glipizide | Glipizide | 54 | 15 |
| Allopurinol | Allopurinol | 53 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 18 |
| Irbesartan | Irbesartan | 52 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 22 |
| Synthroid | Levothyroxine Sodium | 49 | 13 |
| Liothyronine Sodium | Liothyronine Sodium | 43 | 15 |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Farxiga | Dapagliflozin Propanediol | 39 | 12 |
| Januvia | Sitagliptin Phosphate | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 27 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Meloxicam | Meloxicam | 36 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 13 |
| Glimepiride | Glimepiride | 35 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 13 |
| Meclizine Hcl | Meclizine Hcl | 32 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 15 |
| Colchicine | Colchicine | 26 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Prednisone | Prednisone | 24 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Estradiol | Estradiol | 22 | 15 |
| Fluconazole | Fluconazole | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 16 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Lactulose | Lactulose | 20 | 11 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | 11 |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,203.13 · 80 records | Novo Nordisk Inc | AIRSUPRA, AMYVID, ASSURITY, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KISUNLA, LEQVIO, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROCLAIM, REPATHA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, TRELEGY ELLIPTA, Veozah, Wegovy, Xelstrym, ZENPEP, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error